Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Filed with Euronext · · 5 pages · English
In the deck
Story so far
- Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
- Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
- Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Earlier from Sanofi
- Sanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment
- Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
- Communiqué de presse: Sanofi et Cheplapharm créent un nouveau partenariat stratégique autour des médicaments matures
- Sanofi: Information concerning the total number of voting rights and shares - August 2026
- Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
Later from Sanofi
- Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
- Press Release: Availability of the aide-mémoire for Q3 2026 results
- Sanofi: Information concerning the total number of voting rights and shares – September 2026
- Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
- Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded
Follow Sanofi into a list and get an email when it puts out news.
Follow Sanofi